Jim Simons Immunome Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Immunome Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 11,300 shares of IMNM stock, worth $121,588. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,300

Previous 93,300 87.89%

Holding current value

$121,588

Previous $1.13 Million 85.37%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$11.7 - $16.51 $959,399 - $1.35 Million	-82,000 Reduced 87.89%	11,300 $165,000
Q2 2024 Aug 09, 2024	BUY	$11.54 - $22.11 $551,404 - $1.06 Million	47,782 Added 104.97%	93,300 $1.13 Million
Q1 2024 May 13, 2024	SELL	$11.01 - $27.34 $836,561 - $2.08 Million	-75,982 Reduced 62.54%	45,518 $1.12 Million
Q4 2023 Feb 13, 2024	BUY	$7.3 - $10.73 $650,430 - $956,043	89,100 Added 275.0%	121,500 $1.3 Million
Q3 2023 Nov 14, 2023	SELL	$6.17 - $9.16 $74,657 - $110,836	-12,100 Reduced 27.19%	32,400 $271,000
Q2 2023 Aug 11, 2023	BUY	$4.7 - $7.91 $73,320 - $123,396	15,600 Added 53.98%	44,500 $352,000
Q1 2023 May 12, 2023	BUY	$3.26 - $5.69 $25,428 - $44,382	7,800 Added 36.97%	28,900 $144,000
Q4 2022 Feb 13, 2023	SELL	$2.21 - $5.0 $884 - $2,000	-400 Reduced 1.86%	21,100 $47,000
Q2 2022 Aug 12, 2022	BUY	$2.24 - $5.79 $16,800 - $43,425	7,500 Added 53.57%	21,500 $69,000
Q1 2022 May 13, 2022	BUY	$3.88 - $13.99 $54,320 - $195,860	14,000 New	14,000 $80,000
Q3 2021 Nov 12, 2021	SELL	$12.5 - $27.76 $255,000 - $566,304	-20,400 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$16.33 - $32.33 $333,131 - $659,532	20,400 New	20,400 $353,000

Others Institutions Holding IMNM

# of Institutions

129

Shares Held

45.2M

Call Options Held

187K

Put Options Held

65.9K

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $130M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account